New immunotherapy combo tested in aggressive lung cancer
NCT ID NCT07381543
Summary
This study is testing whether adding an immunotherapy drug called adebrelimab to standard chemoradiation helps control limited-stage small cell lung cancer longer. It will compare two approaches: starting immunotherapy early with chemotherapy versus adding it later as maintenance after chemoradiation. The goal is to see which timing works better to delay cancer progression in 76 newly diagnosed patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.